Sanofi

#ACTRIMS2022 ā€“ Tolebrutinib More Potent Than Other BTK Blockers

Tolebrutinib, an investigative inhibitor of Brutonā€™s tyrosine kinase (BTK) being developed byĀ SanofiĀ to treat all forms ofĀ multiple sclerosis (MS), shows the potential to be more potent than other BTK inhibitors also in advanced clinical trials, scientists reported. The findings, based on preclinical data, were shared at the Americas…

FDA Rejects Expansion of Aubagio for Pediatric MS

The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing forms of multiple sclerosis (MS). “The FDA deemed the data submitted were not sufficient to obtain approval of…

#MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show

Janssen Pharmaceuticalsā€™ investigational oral therapy ponesimod is superior to Sanofiā€™s Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssenā€™s MS research program, including on the health…

1st Relapsing MS Patient Enrolls in Phase 3 Trial of Oral SAR442168

A first person has enrolled inĀ Sanofiā€™s Phase 3 trial evaluatingĀ SAR442168, an oral BTK inhibitorĀ intended to treat relapsing forms of multiple sclerosis (MS), Sanofiā€™s partner, Principia Biopharma, announced. ā€œWe are delighted that Sanofi has initiated ā€¦ [this] trial in patients with relapsing MS,ā€ Roy Hardiman, chief…

Aubagio Safely Used by 5 MS Patients With Active COVID-19 Infection

Five people with multiple sclerosis (MS) who tested positive for COVID-19Ā whileĀ being treated with Aubagio (teriflunomide)Ā Ā all developed a mild infection, had good outcomes, and experienced no disease relapses, a case study reported. These findings suggest that use of Aubagio, a disease-modifying therapy that acts on the immune system,…

European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective

A new public-private initiative brings academic and industry researchers from 15Ā European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including multiple sclerosis, so to better predict a patient’s likely response to treatment and likely disease progression. The project, called 3TR…

Denali and Sanofi Partner to Develop Potential Treatments for MS, Other Neurological Disorders

Denali Therapeutics andĀ SanofiĀ will collaborateĀ to develop a compound called DNL747 that may treatĀ multiple sclerosis (MS) and other neurodegenerative disorders. The companies will also jointly work on the development of a separate possible therapy, DNL758, for systemic inflammatory diseases such as rheumatoid arthritis and psoriasis. Both DNL747 and DNL758…

Steering My Own Boat and Making a Splash

The U.K.’s National Health Service (NHS) turned 70 last week. In England, yes, we are mourning our semi-final defeat by Croatia in the World Cup, but to most of us, the NHS is the U.K.’s crowning glory. There are innumerable problems and proposed solutions involving the institution, yet…